BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32273277)

  • 21. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
    Scarfò I; Ormhøj M; Frigault MJ; Castano AP; Lorrey S; Bouffard AA; van Scoyk A; Rodig SJ; Shay AJ; Aster JC; Preffer FI; Weinstock DM; Maus MV
    Blood; 2018 Oct; 132(14):1495-1506. PubMed ID: 30089630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.
    Leung WH; Gay J; Martin U; Garrett TE; Horton HM; Certo MT; Blazar BR; Morgan RA; Gregory PD; Jarjour J; Astrakhan A
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
    Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
    Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
    J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
    Jena B; Maiti S; Huls H; Singh H; Lee DA; Champlin RE; Cooper LJ
    PLoS One; 2013; 8(3):e57838. PubMed ID: 23469246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
    Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.
    Landoni E; Fucá G; Wang J; Chirasani VR; Yao Z; Dukhovlinova E; Ferrone S; Savoldo B; Hong LK; Shou P; Musio S; Padelli F; Finocchiaro G; Droste M; Kuhlman B; Shamshiev A; Pellegatta S; Dokholyan NV; Dotti G
    Cancer Immunol Res; 2021 Apr; 9(4):441-453. PubMed ID: 33547226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells.
    Dwivedi A; Karulkar A; Ghosh S; Srinivasan S; Kumbhar BV; Jaiswal AK; Kizhakeyil A; Asija S; Rafiq A; Kumar S; Nisar A; Patil DP; Poojary MV; Jain H; Banavali SD; Highfill SL; Stroncek DF; Shah NN; Fry TJ; Narula G; Purwar R
    Mol Cancer Ther; 2021 May; 20(5):846-858. PubMed ID: 33632869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
    Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
    Front Immunol; 2020; 11():539654. PubMed ID: 33281809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spatio-temporal biodistribution of
    Sta Maria NS; Khawli LA; Pachipulusu V; Lin SW; Zheng L; Cohrs D; Liu X; Hu P; Epstein AL; Jacobs RE
    Sci Rep; 2021 Jul; 11(1):15077. PubMed ID: 34302002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.